Group 1 - Gilead Sciences' 2026 financial forecast is at the lower end of analyst expectations, leading to a nearly 2% drop in stock price [1] - The company reported Q4 2025 sales and profits slightly above Wall Street expectations, with quarterly sales of its HIV prevention drug Yeztugo reaching $96 million, surpassing the forecast of $88 million [1] - Gilead expects Yeztugo sales to be $800 million in 2026, lower than the analyst forecast of $907 million, with a noted discrepancy from investor expectations of $1 billion [1] Group 2 - Yeztugo has shown nearly 100% effectiveness in clinical trials for HIV prevention, offering hope to curb the annual 1.3 million new infections globally [2] - The annual U.S. list price for Yeztugo is approximately $28,000, causing some hesitation among potential users, although 90% of U.S. payers have agreed to cover the drug's cost [2] - Gilead projects adjusted earnings per share for 2026 to be between $8.45 and $8.85, while analysts expect an average of $8.75, which is 10 cents higher than Gilead's midpoint forecast [2]

Core Points - South Africa has officially approved the new long-acting injectable HIV prevention drug, Lenacapavir, making it the first country in Africa to do so [1] - The drug, developed by Gilead Sciences, requires only two injections per year, providing up to six months of immune protection against HIV [1] - The South African government plans to launch the drug by March 2026, aiming to significantly reduce the annual treatment cost through agreements with Gilead and seven other pharmaceutical companies [1] - Lenacapavir is considered the most effective HIV prevention drug to date, which is particularly significant for South Africa, where the HIV infection rate is high [1] - The FDA has already approved Lenacapavir for HIV prevention in the United States, with a market price of $28,000 per person per year [1]